Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.

A Long Swim co-founder and executive director Doug McConnell sits down with Dr. Hande Ozdinler, A Long Swim Director of Science and Associate Professor of Neurology at Northwestern University, and...

Akava Therapeutics, Inc. announces that on July 6, 2022, orphan drug designation (ODD) status was received for AKV9 for the treatment of amyotrophic lateral sclerosis (ALS) from the U.S. Food...

Richard Silverman was left in the dark for the last five years of clinical development of the drug he discovered. The Northwestern University professor found out about the first approval...

A paper has recently been published demonstrating that AKV9 improves the health of mutant SOD1 mouse upper motor neurons in vitro much better than the FDA-approved ALS drugs riluzole and edaravone, and the combination of AKV9 with either of those drugs provides an additive effect.